Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Factors influencing oncologists’ decisions for germline BRCA testing and adjuvant therapy selection in HER2-negative early breast cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
10.1001/jama.2017.7112 · 2017 · External reference
Unresolved reference
External reference
Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients
10.1200/jco.18.01854 · 2019 · External reference
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic
10.1093/annonc/mdw209 · 2016 · External reference
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
10.1016/s1470-2045(17)30891-4 · 2018 · External reference
Germline BRCA mutation and clinical outcomes in breast cancer patients focusing on survival and failure patterns: a long-term follow-up study of Koreans
10.3390/medicina56100514 · 2020 · External reference
Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer
10.1200/jco.2015.65.0747 · 2016 · External reference
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
10.1186/s13058-020-01349-9 · 2020 · External reference
A systematic review of the international prevalence of BRCA mutation in breast cancer
10.2147/clep.s206949 · 2019 · External reference
The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort
10.1093/jnci/djaa023 · 2020 · External reference
A multigene assay determines risk of recurrence in patients with triple-negative breast cancer
10.1158/0008-5472.can-18-3014 · 2019 · External reference
A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer
10.2217/fon-2022-0310 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Adjuvant olaparib for germline BRCA carriers with HER2-negative early breast cancer: evidence and controversies
10.1093/oncolo/oyad123 · 2023 · External reference
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
10.1038/s41416-024-02827-z · 2024 · External reference
BRCA genetic testing and treatment patterns for patients with HER2-negative early-stage breast cancer in the US community setting
10.3389/fonc.2026.1730548 · 2026 · External reference
Conjoint analysis applications in health–a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force
10.1016/j.jval.2010.11.013 · 2011 · External reference
Understanding uptake of digital health products: methodology tutorial for a discrete choice experiment using the Bayesian efficient design
10.2196/32365 · 2021 · External reference
Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force
10.1016/j.jval.2012.08.2223 · 2013 · External reference
Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force
10.1016/j.jval.2016.04.004 · 2016 · External reference
A choice-based conjoint analysis of the psychiatrist decision-making process used in determining when to discharge adults with major depressive disorder hospitalized for active suicidal ideation with intent
10.1097/nmd.0000000000001463 · 2022 · External reference
Unresolved reference
External reference
VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
10.1016/j.annonc.2021.06.014 · 2021 · External reference
Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer
10.1056/nejmoa2105215 · 2021 · External reference
Event-free survival with pembrolizumab in early triple-negative breast cancer
10.1056/nejmoa2112651 · 2022 · External reference
Adjuvant capecitabine for breast cancer after preoperative chemotherapy
10.1056/nejmoa1612645 · 2017 · External reference
Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)
10.1200/jco.20.02514 · 2020 · External reference
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
10.1016/j.annonc.2021.09.015 · 2021 · External reference
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study
10.3389/fonc.2023.1152123 · 2023 · External reference
Pembrolizumab for early triple-negative breast cancer
10.1056/nejmoa1910549 · 2020 · External reference
LBA18 pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: updated EFS results from the phase III KEYNOTE-522 study
10.1016/j.annonc.2023.10.008 · 2023 · External reference
Unresolved reference
2023 · External reference
Unresolved reference
2024 · External reference
Unresolved reference
2022 · External reference
St. Gallen/Vienna 2023: Optimization of treatment for patients with primary breast cancer - a brief summary of the consensus discussion
10.1159/000530584 · 2023 · External reference
Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2023.11.016 · 2024 · External reference
Physician response to surveys. A review of the literature
10.1016/s0749-3797(00)00258-0 · 2001 · External reference
G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences
10.3758/bf03193146 · 2007 · External reference
Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline
10.1200/jco.23.02225 · 2024 · External reference
Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons
10.1245/s10434-019-07549-8 · 2019 · External reference
Unresolved reference
External reference
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
10.1016/s1470-2045(20)30324-7 · 2020 · External reference
Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer
10.1001/jamaoncol.2019.1029 · 2019 · External reference
10.1158/1538-7445.sabcs23-gs01-05
10.1158/1538-7445.sabcs23-gs01-05 · External reference
Abstract GS1-09: OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer
10.1158/1557-3265.sabcs24-gs1-09 · 2025 · External reference
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
10.1016/j.annonc.2022.09.159 · 2022 · External reference
Factors influencing patient preferences for BRCA testing and adjuvant therapy in HER2-negative early breast cancer in the United States: Best–worst scaling and discrete choice experiment
10.1007/s40271-025-00783-1 · 2026 · External reference
